Caribou Biosciences, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $11.2M | $10.0M | $34.5M | $13.9M | $9.6M |
| Operating income | -$148.3M | -$166.6M | -$116.1M | -$106.4M | -$67.0M |
| Operating expenses | $159.5M | $176.6M | $150.5M | $120.2M | $76.6M |
| Cash from operations | -$111.0M | -$138.2M | -$93.3M | -$91.0M | -$32.5M |
| Capital expenditure | $1.4M | $4.9M | $11.6M | $6.5M | $2.1M |
| Free cash flow | -$112.4M | -$143.1M | -$104.9M | -$97.4M | -$34.6M |
| Impairments | $12.2M | $0 | — | — | — |
| Total assets | $175.4M | $313.3M | $432.2M | $373.8M | $442.4M |
| Total liabilities | $53.2M | $60.4M | $63.8M | $72.9M | $54.5M |
Shares outstanding 99.2M · Free float 91.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.